Kornimate/medical-research-clean huggingface dataset:
therapeutic listening in patients with colorectal cancer

Conditions: Anxiety; Fear

Summary: this is a randomized clinical trial that aims to investigate the effect of therapeutic listening anxiety and preoperative fear of patients hospitalized for surgical treatment of colorectal cancer. physiological variables will be evaluated (heart rate, blood pressure and respiratory rate), cortisol and salivary amylase and anxiety scores by state-trait anxiety inventory and fear for surgery fear questionnaire. the data of the variables will be compared at two different times (before and after the intervention).

to calculate the sample size was chosen when using numerical scale idate. considering that you want to detect a difference of 10 points (δ) in the range with a significance level of 5% (z1-α = 1.96), a power of 80% (z1-β = 1.96). the result obtained was 25 subjects for each group. information related to variances of control and intervention groups were obtained through the pilot study and a correlation of 0.5 was assumed.

Eligibility criteria:
inclusion criteria: * be 18 years of age; * be hospitalized for performing surgical oncology; * not be performing another treatment for cancer; * not be participating in another study; * be clinically well and / or stable (have score less than or equal to 3 by the eastern cooperative oncology group - performance status). exclusion criteria: * being illiterate, a condition that will prevent the participant to answer the questionnaires and instruments of the study, which are self-administered; * be in possession of psychiatric disorders; * be using medication containing corticosteroids.

Keywords: anxiety fear colorectal surgery colorectal neoplasms
clinical performance comparison of several different contact lenses

Conditions: Myopia

Summary: the purpose of the study is to evaluate the possible benefits of second generation silicone hydrogel contact lenses.


Eligibility criteria:
inclusion criteria: subjects must: * be existing soft contact lens wearers of the study control lenses * require a distance visual correction in both eyes * have a contact lens spherical distance requirement between -1.00 diopters (d) and -8.00d in both eyes * have astigmatism less than or equal to 1.00d in both eyes * be able to wear lenses available for this study * be corrected to a visual acuity of 6/9 (20/30) or better in each eye * have normal eyes with no evidence of abnormality or disease exclusion criteria: subject are excluded for the following reasons: * monovision corrected * worn lenses extended wear in the last 3 months. * require concurrent ocular medication * grade 3 or 4 abnormalities * grade 3 corneal staining in more than two regions * anterior ocular surgery * any other ocular surgery or injury within 8 weeks prior to study enrollment * abnormal lachrymal secretions * pre-existing ocular irritation that would preclude contact lens fitting * corneal irregularities * polymethyl methacrylate (pmma) or rigid gas permeable (rgp) lens wear in past 12 weeks * any systemic illness which would preclude contact lens wear * diabetes * infectious or immunosuppressive disease * pregnancy or lactating, or planning pregnancy at time or enrollment * participating in a concurrent clinical study or within last 60 days * allergy to the standardized study care solution
the effectiveness of paritaprevir/ritonavir - ombitasvir, ± dasabuvir, ± ribavirin in france

Conditions: Chronic Hepatitis C

Summary: this study seeks to determine the effectiveness of the interferon-free abbvie regimen ± ribavirin (rbv) in participants with chronic hepatitis c (chc) virus in clinical practices across france.


Eligibility criteria:
inclusion criteria: * treatment-naïve or -experienced participants with confirmed chc, genotype 1 or 4 * participants receiving or who will receive the interferon-free abbvie regimen ± rbv according to product label * rbv prescribed in line with the current local label exclusion criteria: * participant is not participating or intending to participate in a concurrent interventional therapeutic trial

Keywords: hcv chronic hepatitis c
effect of early management on pain and depression in patients with pancreatobiliary cancer, epade-pb

Conditions: Pancreatic Cancer; Biliary Tract Cancer; Cancer Pain; Depression

Summary: effect of early management on pain and depression in patients with pancreatobiliary cancer, epade-pb purpose to determine whether early palliative care integrated with usual oncologic care with automated symptom monitoring can improve depression and pain in patients with cancer


Eligibility criteria:
inclusion criteria: * ages eligible for study: 18 years and older genders eligible for study: both accepts healthy volunteers: no * pathologic confirmed locally advanced or metastatic pancreatic cancer or biliary tract cancer * within 8 weeks after diagnosis * cancer-related pain (brief pain inventory \[bpi\] worst pain score \>3), depression (center for epidemiological studies-depression scale \[ces-d\] \>16) or both * karnofsky performance rating scale ≥50% exclusion criteria: * opioid intolerance * history of drug or alcohol abuse * impaired sensory or cognitive function * pregnant or lactating woman * women of child bearing potential not using a contraceptive method * sexually active fertile men not using effective birth control during medication of study drug and up to 6 months after completion of study drug if their partners are women of child-bearing potential

Keywords: pancreatic cancer biliary tract cancer cancer pain depression
china health big data

Conditions: Osteoporosis; Obesity; Liver Steatoses

Summary: in this nationwide multi center study the investigators combine the low dose chest ct scan data with qct technology, to measure the bmd of spine, vat and liver fat in the health check subjects. the aim of this study is to evaluate the performance of qct in the health check field, and further to evaluate the prevalence of osteoporosis, obesity and liver steatosis in health check population across china.

low dose chest ct scan is the standard for lung cancer in the health check center in china. quantitative computed tomography (qct) is utilizing the ct raw data to measure the bone mineral density (bmd), the visceral fat (vat) and liver fat content in human, which can be widely used in the diagnosis of osteoporosis, the assessment of obesity and liver steatosis. in this nationwide multi center study the investigators combine the low dose chest ct scan data with qct technology, to measure the bmd of spine, vat and liver fat in the health check subjects. this study is to evaluate the performance of qct in the health check field, and further to evaluate the prevalence of osteoporosis, obesity and liver steatosis in health check population across china.

Eligibility criteria:
inclusion criteria: health check subjects 30-90 years old low dose chest ct scan exclusion criteria: pregnant women metal implant in the ct scan area

Keywords: bone mineral density, quantitative computed tomography, osteoporosis, obesity, liver steatosis
a blinded study comparing the safety and efficacy of a fully human anti-il8 monoclonal antibody (abx-il8) to placebo in patients with chronic bronchitis and copd

Conditions: Pulmonary Disease, Chronic Obstructive; Bronchitis, Chronic

Summary: to determine if abx-il8 will improve shortness of breath.

chronic obstructive pulmonary disease (copd) is defined as a disease state characterized by the presence of airflow obstruction due to chronic bronchitis or emphysema. the airflow obstruction is generally progressive, may be accompanied by airway hyper-reactivity, and may be partially reversible. inflammation in the lungs is triggered by exposure to inhaled toxic substances that can lead to tissue damage, mucous secretion, airways narrowing and tissue destruction. interleukin-8 (il-8) plays a major role in elevating sputum in patients with copd and may contribute to tissue destruction. therefore, the highly specific antibody to il-8 (such as abx-il8) may help to reduce mucous production and tissue destruction.

Eligibility criteria:
inclusion criteria: * \> 50 years old * \> 20 pack-year of smoking * diagnosed with copd and chronic bronchitis exclusion criteria: * patients with bronchiectasis, cystic fibrosis, tuberculosis, asthma, alpha-1 antitrypsin deficiency, chf * require oxygen therapy * uncontrolled hypertension * hiv or hepatitis * recent history of copd exacerbation * patients with cancer * recent history of infection

Keywords: copd chronic bronchitis chronic obstructive pulmonary disease shortness of breath dyspnea bronchitis
citrulline supplementation combined with exercise: effect on muscle function in elderly people (citex study)

Conditions: Sarcopenia; Obesity

Summary: the main objective of this study is to determine if oral supplementation of citrulline, when combined with hiit, can produce significant changes in body composition, muscle quality, muscle metabolism and functional capacity in older obese men and women . the investigators hypothesize that citrulline combined with hiit will be more beneficial than hiit alone which will be more beneficial than citrulline alone which will be more beneficial than placebo alone in obese elderly men and women .

citrulline is a non-protein amino acid, isolated from watermelon, involved in the urea cycle and an arginine precursor. participants will take 10g/d of citrulline or placebo (isocaloric). high intensity interval training (hiit) is a high intensity aerobic training (30 sec at 85% and up of hrmax + 1min30 at 65-70% of hrmax). they hiit duration is 30 min/session. hiit is recognized as beneficial to improve health in human such as vo2max, body fat or . then intervention will be follow during 12 consecutive weeks.

Eligibility criteria:
inclusion criteria: 1. autonomous (being able to follow the exercise program) and without cognitive impairment (moca test ≥21) ; 2. obese status (bmi between 30 and 40 kg / m2 or a waist circumference greater than 102 cm for men and 88 cm for women or fat mass (%; total or androïd or gynoïd) equal or superior to 27% in men and 40% in women; 3. stable weight (± 5 kg) for 6 months; 4. non-smoking and moderate drinkers (max: 15 g/day of alcohol) ; 5. without stroke or history of stroke ; 6. sedentary (less than 2 hours of structured physical activity per week); 7. not being involved in a vigorous exercise program for at least 12 months; 8. can understand french 9. postmenopausal women (without menses since 60 consecutively months). exclusion criteria: 1. to have a metal implant (pacemaker); 2. asthma requiring oral steroid treatment; 3. taking other medication that could affect metabolism or cardiovascular function; 4. taking anticoagulant medication. 5. taking hormonal-replacement therapy (only for women)

Keywords: muscle function functional capacity
primary prevention trial of the health effects of antioxidant vitamins and minerals.

Conditions: Healthy

Summary: it has been suggested that a low dietary intake of antioxidant vitamins and minerals increases the incidence rate of cardiovascular disease and cancer. to date, however, the published results of randomized, placebo-controlled trials of supplements containing antioxidant nutrients have not provided clear evidence of a beneficial effect. we tested the efficacy of nutritional doses of supplementation with a combination of antioxidant vitamins and minerals in reducing the incidence of cancer and ischemic cardiovascular disease in the general population.

from experimental studies it is known that free radicals may induce numerous pathological processes, and it has been suggested that, because of their antioxidant capacity, nutrients such as beta-carotene, vitamin c, vitamin e, selenium and zinc may prevent such harmful effects. epidemiological data from cross-sectional, case-control, and prospective studies have indeed shown a strong relationship between the intake of antioxidant vitamins and minerals, or foods rich in these nutrients, and the risk of cancer and ischaemic cardiovascular diseases (cvd). however, randomised placebo-controlled primary prevention trials, in which antioxidant micronutrients alone or in pairs were given at high doses over long periods, have not been able to prove this potential beneficial effect, and two of these even suggested harmful effects. the seemingly contradictory results between the observational studies and these randomised trials can be explained by the fact that the doses used in clinical trials were much higher than the highest levels reachable by usual dietary intake which have been found to be associated in observational studies with the lowest risk of cancer and cvd. in fact, the only trial which did observe a beneficial effect on total mortality and cancer incidence used nutritional doses of a combination of several vitamins and minerals and was performed on chinese population with very low baseline micronutrient status, due to poor life conditions in this region (9). the objective of the "supplementation en vitamines et minéraux antioxydants" (su.vi.max) study, was to test in a randomised, placebo-controlled trial, if an adequate and well balanced intake of antioxidant nutrients reduces the incidence of cancers and ischaemic cardiovascular diseases in a middle-age general population.

Eligibility criteria:
inclusion criteria: * women aged 35-60 years, men aged 45-60 years * acceptance of the possibility to be given a placebo and acceptance of the constraints of participation * lack of previous regular supplementation with any of the vitamins or minerals in the supplement provided * absence of extreme beliefs or behavior regarding diet exclusion criteria: * disease likely to hinder active participation or threatened 5-year survival

Keywords: prevention trial antioxydant vitamins and minerals cancer ischemic disease mortality health related quality of life
exploratory clinical study on fasting in psoriasis and psoriatic arthritis (risefast)

Conditions: Psoriasis Arthritis; Psoriasis (PsO)

Summary: the risefast pilot study will investigate the clinical, metabolic and immunological effects of fasting and plant-based diet (pbd) on patients with psoriasis (pso) and psoriatic arthritis (psa) on their gut microbiota. the project will combine clinical assessments, cytometric profiling, and gut microbiota analysis to explore the relationship between fasting, a plant-based diet, and psoriatic disease. the study includes a 7-day fasting period followed by 11 weeks of pbd, with the goal of improving disease activity, quality of life, and understanding the role of gut microbiota in these conditions. this approach could lead to low-cost, accessible therapeutic options with minimal side effects.

psoriatic disease, encompassing psoriasis (pso) and psoriatic arthritis (psa) is a chronic inflammatory condition influenced by genetic, immune, and environmental factors, particularly diet and gut microbiota. while biologics and dmards have improved disease management, treatment responses vary, and long-term remission remains difficult. continuous inflammation control often requires pharmacological treatment, highlighting the need for adjunctive therapies. emerging research links gut microbiota imbalances (dysbiosis) to chronic inflammation, suggesting that dietary interventions could offer therapeutic benefits. fasting and plant-based diets (pbd) may help regulate immune responses and gut microbiota composition. fasting has been shown to reduce oxidative stress, promote autophagy, and alter immune cell dynamics, while pbd is associated with anti-inflammatory effects and enhanced microbial diversity. the risefast pilot study aims to investigate whether a seven-day fasting period followed by a structured pbd can improve disease activity, quality of life, and gut microbiota in pso and psa patients. while prior studies suggest potential benefits, their specific effects on psoriatic disease remain unclear. by integrating clinical, microbiome, and immune profiling, the study aims to clarify dietary impacts on inflammation.

Eligibility criteria:
inclusion criteria: * active plaque psoriasis (pasi ≥3) or psoriatic arthritis fulfilling the classification criteria for psoriatic arthritis (caspar) and not meeting mda criteria * on stable baseline psoriatic treatment for 12 weeks before enrollment * ≥ 18 years old exclusion criteria: * pregnancy or breastfeeding * underweight (bmi ≤18,5) * eating disorder in the last 5 years * severe internal diseases (e.g. renal insufficiency with creatinine \> 2mg/dl) * current practice of vegan diet or fasting within the past 6 months * use of antibiotics within the past 3 months

Keywords: fasting vegan plant-based diet psoriasis
resistance to aspirin and/or clopidogrel among patients with pad.

Conditions: Intermittent Claudication

Summary: 263 patients with peripheral atherosclerosis were examined to evaluate the activity of the platelets during the standard treatment, including aspirin. a subgroup of 43 received 600 mg of clopidogrel 2 h before platelet reactivity analysis. the main hypothesis is that high platelet activity at the beginning of the study is associated with a higher risk of atherothrombosis. follow up time is 5 years.

patients with peripheral atherosclerosis are at high risk of atherothrombosis, mainly heart attack and stroke. the medical treatment of these patients include platelet inhibiting drugs, usually aspirin, to reduce the risk of ischemic events. clopidogrel is another platelet inhibiting drug, which is prescribed less often, primarily because of the high costs compared to aspirin. phenomena of 'resistance' to these drugs have been described by numerous investigators. essentially resistance means that the effect of the drug described is less than expected or missing, as measured by various laboratory methods. we do not know which way resistance is best described, but it has been described that patients who are 'resistant' to either drug are less protected against future heart attacks or strokes. main objectives: * to measure the activity of platelets in these patients during aspirin treatment. * to measure the activity of platelets in a minor population of these patients during clopidogrel treatment. * to evaluate the prognostic significance of resistance to aspirin in these patients. methods: platelet activity is measured by the pfa-100 (dade behring) and by traditional turbidimetric aggregation. endpoints: myocardial infarction, unstable angina, cerebral infarction, transitory cerebral ischaemia, sudden deterioration of symptoms, percutaneous or surgical vascular intervention, amputation, death.

Eligibility criteria:
inclusion criteria: * atherosclerosis of the lower limbs, defined by one of the following criteria: ankle-brachial pressure index (abpi)\< 0.9, intermittent claudication, ischaemic pain at rest, ischaemic ulcers or gangrene. * age \> 18 years * for fertile women: use of safe contraception (intrauterine contraceptive device, the pill, hormonal skin patches, progestogen injections, progestogen implant, vaginal ring) exclusion criteria: * allergy to either aspirin or clopidogrel * known bleeding disorder * platelet count \ 400 mia/l * intake of nsaid's, ssri's or dipyridamol within the preceding 14 days * not radically treated gastrointestinal ulceration within the last 6 month * greater surgical procedures performed within the last 3 month * severe renal disease * severe hepatic disease * breast feeding * pregnancy

Keywords: intermittent claudication aspirin resistance clopidogrel resistance
a study to evaluate vimseltinib in adults with active chronic graft-versus-host disease (cgvhd)

Conditions: Chronic Graft-Versus-Host Disease (cGVHD)

Summary: the purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cgvhd. participants will be treated with vimseltinib in 28-day treatment cycles for approximately 2 years.


Eligibility criteria:
inclusion criteria: 1. must be allogeneic hematopoietic stem cell transplant (hsct) recipients with moderate to severe cgvhd requiring systemic immune suppression. a. may have persistent active gvhd (agvhd) and chronic gvhd (cgvhd) manifestations (overlap syndrome). 2. participants with active cgvhd who have received and failed at least 2 prior lines of systemic therapy. 3. stable dose of systemic corticosteroids is permitted but not required. if being taken, participants should be on a stable dose of corticosteroids for at least 2 weeks prior to starting study drug treatment. 4. adequate organ and bone marrow functions. 5. participants of reproductive potential agree to follow the contraception requirements. 6. karnofsky performance scale (kps) of ≥60. exclusion criteria: 1. has agvhd without manifestations of cgvhd. 2. prior use of colony-stimulating factor 1 receptor (csf1r) inhibitor for cgvhd. 3. history or other evidence of severe illness, uncontrolled infection, or any other conditions that would make the participant unsuitable for the study. 4. history of malignancy except for: 1. underlying malignancy for which the transplant was performed 2. malignancy treated with curative intent and with no evidence of active disease present for more than 3 years prior to enrollment and felt to be at low risk for recurrence. 5. malabsorption syndrome or other illness that could affect oral absorption.

Keywords: allogeneic hematopoietic stem cell transplant (hsct) graft-versus-host disease gvhd cgvhd graft versus host disease immune system diseases organizing pneumonia bronchiolitis obliterans bronchiolitis bronchial diseases respiratory tract diseases lung diseases, obstructive lung diseases bronchiolitis obliterans syndrome graft vs host disease sclerosis fibrosis hematopoietic stem cell transplantation liver diseases